María Hayón-Ponce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Hayón-Ponce has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Araceli Muñoz-Garach
Department of Endocrinology and Nutrition, Virgen de las Nieves University Hospital, 18014 Granada, Spain
2 shared publications - Jose M. Romero Márquez
Department of Endocrinology and Nutrition, Virgen de las Nieves University Hospital, 18014 Granada, Spain
2 shared publications - Aida Elhadri-Egea
Department of Endocrinology and Nutrition, Virgen de las Nieves University Hospital, 18014 Granada, Spain
1 shared publication - Alejandro Grau-Perales
Center for Neural Science, New York University
1 shared publication - Beatriz García-Fontana
Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), 18012 Granada, Spain
1 shared publication - Blanca Riquelme-Gallego
Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (3) , 39
Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study
Background: Type 2 diabetes mellitus is commonly associated with obesity, metabolic liver disease, and chronic low-grade inflammation. Semaglutide is known to improve glycaemic control and body weight, but its real-world associations with hepatic markers, fibrosis-related indices, and systemic inflammatory parameters remain incompletely characterized. This study evaluated changes in metabolic, hepatic, and inflammatory parameters during injectable semaglutide treatment and explored whether these changes differed according to baseline disease status. Methods: A retrospective observational study was conducted in patients with type 2 diabetes treated with injectable semaglutide 1 mg/week and followed for six months. Anthropometric, metabolic, hepatic, and inflammatory variables were collected at baseline and follow-up, including liver enzymes, the Fibrosis-4 (FIB-4) index, and the systemic immune–inflammation (SII) index. Analyses included correlation analyses and exploratory stratification according to baseline fibrosis risk and inflammatory status. Results: Semaglutide treatment was associated with significant reductions in body weight, body mass index, fasting glucose, HbA1c, and triglyceride levels. Alanine and aspartate aminotransferase levels decreased significantly, consistent with a reduction in liver enzyme abnormalities during follow-up. No significant overall changes were observed in FIB-4, an indirect fibrosis-related index, or in SII, an indirect hematological inflammatory index. However, exploratory stratified analyses suggested that patients with higher baseline FIB-4-estimated fibrosis risk or elevated SII values showed greater reductions in these indices, whereas those with low baseline risk showed no relevant changes. Conclusions: In routine clinical practice, six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus. Findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices and the baseline-dependent patterns observed were exploratory and hypothesis-generating.
- 27 July 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (3) , 39
Open AccessEffectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study
Background: Type 2 diabetes mellitus is commonly associated with obesity, metabolic liver disease, and chronic low-grade inflammation. Semaglutide is known to improve glycaemic control and body weight, but its real-world associations with hepatic markers, fibrosis-related indices, and systemic inflammatory parameters remain incompletely characterized. This study evaluated changes in metabolic, hepatic, and inflammatory parameters during injectable semaglutide treatment and explored whether these changes differed according to baseline disease status. Methods: A retrospective observational study was conducted in patients with type 2 diabetes treated with injectable semaglutide 1 mg/week and followed for six months. Anthropometric, metabolic, hepatic, and inflammatory variables were collected at baseline and follow-up, including liver enzymes, the Fibrosis-4 (FIB-4) index, and the systemic immune–inflammation (SII) index. Analyses included correlation analyses and exploratory stratification according to baseline fibrosis risk and inflammatory status. Results: Semaglutide treatment was associated with significant reductions in body weight, body mass index, fasting glucose, HbA1c, and triglyceride levels. Alanine and aspartate aminotransferase levels decreased significantly, consistent with a reduction in liver enzyme abnormalities during follow-up. No significant overall changes were observed in FIB-4, an indirect fibrosis-related index, or in SII, an indirect hematological inflammatory index. However, exploratory stratified analyses suggested that patients with higher baseline FIB-4-estimated fibrosis risk or elevated SII values showed greater reductions in these indices, whereas those with low baseline risk showed no relevant changes. Conclusions: In routine clinical practice, six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus. Findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices and the baseline-dependent patterns observed were exploratory and hypothesis-generating.
- Open Access
Incremental Prognostic Value of the CONUT Score for In-Hospital Mortality and Length of Stay in Hospitalized Patients
Background: Disease-related malnutrition is highly prevalent among hospitalized patients and is associated with increased mortality, complications, and prolonged hospital stays. Early identification of patients at nutritional risk is therefore essential to improve clinical outcomes. The Controlling Nutritional Status (CONUT) score is an objective prognostic immunometabolic marker derived from serum albumin, total cholesterol, and lymphocyte count. This study aimed to evaluate the prognostic value of the CONUT score for in-hospital mortality and length of hospital stay (LOS) in hospitalized patients with moderate-to-severe nutritional risk and to determine whether incorporating CONUT improves the predictive performance of a clinical model based on routine admission variables. Methods: A retrospective observational cohort study was conducted, including 671 adult patients admitted to a tertiary university hospital with CONUT ≥ 6. Multivariable logistic regression was used to assess predictors of in-hospital mortality, while LOS was analyzed using multivariable linear regression. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC). Results: Higher CONUT scores were independently associated with increased in-hospital mortality. Each one-point increase in CONUT was associated with 28% higher odds of death (OR 1.28; 95% CI 1.13–1.46; p < 0.001). Patients with a severe CONUT score had significantly higher mortality compared with those with a moderate CONUT score (OR 1.77; 95% CI 1.12–2.81; p = 0.004). Incorporating CONUT into the clinical prediction model significantly improved discrimination, increasing the AUC from 0.728 to 0.753 (DeLong p = 0.035). Higher CONUT values were also associated with longer hospital stays: each additional point corresponded to a 5.4% increase in LOS (p = 0.009), and a severe CONUT score was associated with a 17.6% longer stay (p = 0.027). Conclusions: the CONUT score is independently associated with in-hospital mortality and prolonged hospitalization. While its incremental discriminative improvement is modest, its automated calculation from routine laboratory data makes it a practical and scalable tool for early risk stratification.
Open AccessIncremental Prognostic Value of the CONUT Score for In-Hospital Mortality and Length of Stay in Hospitalized Patients
Background: Disease-related malnutrition is highly prevalent among hospitalized patients and is associated with increased mortality, complications, and prolonged hospital stays. Early identification of patients at nutritional risk is therefore essential to improve clinical outcomes. The Controlling Nutritional Status (CONUT) score is an objective prognostic immunometabolic marker derived from serum albumin, total cholesterol, and lymphocyte count. This study aimed to evaluate the prognostic value of the CONUT score for in-hospital mortality and length of hospital stay (LOS) in hospitalized patients with moderate-to-severe nutritional risk and to determine whether incorporating CONUT improves the predictive performance of a clinical model based on routine admission variables. Methods: A retrospective observational cohort study was conducted, including 671 adult patients admitted to a tertiary university hospital with CONUT ≥ 6. Multivariable logistic regression was used to assess predictors of in-hospital mortality, while LOS was analyzed using multivariable linear regression. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC). Results: Higher CONUT scores were independently associated with increased in-hospital mortality. Each one-point increase in CONUT was associated with 28% higher odds of death (OR 1.28; 95% CI 1.13–1.46; p < 0.001). Patients with a severe CONUT score had significantly higher mortality compared with those with a moderate CONUT score (OR 1.77; 95% CI 1.12–2.81; p = 0.004). Incorporating CONUT into the clinical prediction model significantly improved discrimination, increasing the AUC from 0.728 to 0.753 (DeLong p = 0.035). Higher CONUT values were also associated with longer hospital stays: each additional point corresponded to a 5.4% increase in LOS (p = 0.009), and a severe CONUT score was associated with a 17.6% longer stay (p = 0.027). Conclusions: the CONUT score is independently associated with in-hospital mortality and prolonged hospitalization. While its incremental discriminative improvement is modest, its automated calculation from routine laboratory data makes it a practical and scalable tool for early risk stratification.
- Open Access
- 20 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2209
Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients
Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p < 0.001). We found a progressive increase in serum OGN according to the severity of kidney impairment in T2D patients (normal kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90) ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction in T2D patients.
- 20 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2209
Open AccessOsteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients
Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p < 0.001). We found a progressive increase in serum OGN according to the severity of kidney impairment in T2D patients (normal kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90) ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction in T2D patients.